Global Pipeline Review for High Affinity Nerve Growth Factor Receptor - H1 2020 - ResearchAndMarkets.com

DUBLIN--()--The "High Affinity Nerve Growth Factor Receptor - Pipeline Review, H1 2020" drug pipelines has been added to ResearchAndMarkets.com's offering.

This latest report outlays comprehensive information on the High Affinity Nerve Growth Factor Receptor (Neurotrophic Tyrosine Kinase Receptor Type 1 or TRK1 Transforming Tyrosine Kinase Protein or Tropomyosin Related Kinase A or Tyrosine Kinase Receptor or gp140trk or p140 TrkA or NTRK1 or EC 2.7.10.1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

It also reviews key players involved in High Affinity Nerve Growth Factor Receptor (Neurotrophic Tyrosine Kinase Receptor Type 1 or TRK1 Transforming Tyrosine Kinase Protein or Tropomyosin Related Kinase A or Tyrosine Kinase Receptor or gp140trk or p140 TrkA or NTRK1 or EC 2.7.10.1) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for High Affinity Nerve Growth Factor Receptor
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding High Affinity Nerve Growth Factor Receptor development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Companies Mentioned

  • Allergan Plc
  • AlzeCure Pharma AB
  • AnHeart Therapeutics Inc
  • Bayer AG
  • Chugai Pharmaceutical Co Ltd
  • Dompe Farmaceutici SpA
  • F. Hoffmann-La Roche Ltd
  • Handok Inc
  • Merck & Co Inc
  • Neurodegeneration Therapeutics Inc
  • Oncology Venture A/S
  • Pfizer Inc
  • Purdue Pharma LP
  • Rottapharm Biotech Srl
  • Sienna Biopharmaceuticals Inc
  • Tiziana Life Sciences Plc

Scope

  • The report provides a snapshot of the global therapeutic landscape for High Affinity Nerve Growth Factor Receptor
  • The report reviews High Affinity Nerve Growth Factor Receptor targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in High Affinity Nerve Growth Factor Receptor targeted therapeutics and enlists all their major and minor projects
  • The report assesses High Affinity Nerve Growth Factor Receptor targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to High Affinity Nerve Growth Factor Receptor targeted therapeutics

Key Topics Covered:

  • Introduction
  • Report Coverage
  • High Affinity Nerve Growth Factor Receptor - Overview
  • High Affinity Nerve Growth Factor Receptor - Therapeutics Development
  • Products under Development by Stage of Development
  • Products under Development by Therapy Area
  • Products under Development by Indication
  • Products under Development by Companies
  • Products under Development by Universities/Institutes
  • High Affinity Nerve Growth Factor Receptor - Therapeutics Assessment
  • Assessment by Mechanism of Action
  • Assessment by Route of Administration
  • Assessment by Molecule Type
  • High Affinity Nerve Growth Factor Receptor - Companies Involved in Therapeutics Development
  • High Affinity Nerve Growth Factor Receptor - Drug Profiles
  • ACD-855 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • High Affinity Nerve Growth Factor Receptor - Dormant Products
  • High Affinity Nerve Growth Factor Receptor - Discontinued Products
  • High Affinity Nerve Growth Factor Receptor - Product Development Milestones
  • Featured News & Press Releases
  • Appendix

For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/whzmt

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900